This page shows the latest Naxitamab news and features for those working in and with pharma, biotech and healthcare.
The BLA will cover the use of naxitamab in combination with GM-CSF – a white blood cell stimulating drug – in relapsed/refractory high-risk neuroblastoma patients. ... Y-mAbs reported new results from its main phase 3 naxitamab study at the
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...